Personalized Reminders for Immunization Using Short Messaging Systems to Improve Human Papillomavirus Vaccination Series Completion: Parallel-Group Randomized Trial.
adolescent
human papillomavirus
mHealth
minority health
mobile health
mobile phone
mobile reminders
smartphone
text messaging
text reminders
transtheoretical model
vaccine completion
vaccine decision-making
vaccine education
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
27 12 2021
27 12 2021
Historique:
received:
15
02
2021
accepted:
13
10
2021
revised:
09
07
2021
entrez:
27
12
2021
pubmed:
28
12
2021
medline:
2
2
2022
Statut:
epublish
Résumé
Completion rates among adolescents who initiate the human papillomavirus (HPV) vaccine 3-dose series are low. SMS text message vaccine reminders are effective, but less is known about the best types for HPV series completion or the ability to assess and target vaccine decision-making stage. The aim of this study is to compare the effectiveness of HPV vaccine series completion in minority adolescents who received precision and educational versus conventional SMS text message reminders. Enrolled parents of adolescents aged 9-17 years who received the first HPV vaccine dose at 1 of the 4 academic-affiliated community health clinics in New York City were randomized 1:1 to 1 of the 2 parallel, unblinded arms: precision SMS text messages (which included stage-targeted educational information, next dose due date, and site-specific walk-in hours) or conventional SMS text messages without educational information. Randomization was stratified according to gender, age, and language. The primary outcome was series completion within 12 months. In post hoc analysis, enrollees were compared with concurrent nonenrollees and historical controls. Overall, 956 parents were enrolled in the study. The precision (475 families) and conventional (481 families) SMS text message arms had similarly high series completion rates (344/475, 72.4% vs 364/481, 75.7%). A total of 42 days after the first dose, two-thirds of families, not initially in the preparation stage, moved to preparation or vaccinated stage. Those in either SMS text message arm had significantly higher completion rates than nonenrollees (708/1503, 47.1% vs 679/1503, 45.17%; P<.001). Even after removing those needing only 2 HPV doses, adolescents receiving any SMS text messages had higher completion rates than historical controls (337/2823, 11.93% vs 981/2823, 34.75%; P<.001). A population-wide effect was seen from 2014 to 2016, above historical trends. SMS text message reminders led to timely HPV vaccine series completion in a low-income, urban, minority study population and also led to population-wide effects. Educational information did not provide an added benefit to this population. ClinicalTrials.gov NCT02236273; https://clinicaltrials.gov/ct2/show/NCT02236273.
Sections du résumé
BACKGROUND
Completion rates among adolescents who initiate the human papillomavirus (HPV) vaccine 3-dose series are low. SMS text message vaccine reminders are effective, but less is known about the best types for HPV series completion or the ability to assess and target vaccine decision-making stage.
OBJECTIVE
The aim of this study is to compare the effectiveness of HPV vaccine series completion in minority adolescents who received precision and educational versus conventional SMS text message reminders.
METHODS
Enrolled parents of adolescents aged 9-17 years who received the first HPV vaccine dose at 1 of the 4 academic-affiliated community health clinics in New York City were randomized 1:1 to 1 of the 2 parallel, unblinded arms: precision SMS text messages (which included stage-targeted educational information, next dose due date, and site-specific walk-in hours) or conventional SMS text messages without educational information. Randomization was stratified according to gender, age, and language. The primary outcome was series completion within 12 months. In post hoc analysis, enrollees were compared with concurrent nonenrollees and historical controls.
RESULTS
Overall, 956 parents were enrolled in the study. The precision (475 families) and conventional (481 families) SMS text message arms had similarly high series completion rates (344/475, 72.4% vs 364/481, 75.7%). A total of 42 days after the first dose, two-thirds of families, not initially in the preparation stage, moved to preparation or vaccinated stage. Those in either SMS text message arm had significantly higher completion rates than nonenrollees (708/1503, 47.1% vs 679/1503, 45.17%; P<.001). Even after removing those needing only 2 HPV doses, adolescents receiving any SMS text messages had higher completion rates than historical controls (337/2823, 11.93% vs 981/2823, 34.75%; P<.001). A population-wide effect was seen from 2014 to 2016, above historical trends.
CONCLUSIONS
SMS text message reminders led to timely HPV vaccine series completion in a low-income, urban, minority study population and also led to population-wide effects. Educational information did not provide an added benefit to this population.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02236273; https://clinicaltrials.gov/ct2/show/NCT02236273.
Identifiants
pubmed: 34958306
pii: v9i12e26356
doi: 10.2196/26356
pmc: PMC8749571
doi:
Substances chimiques
Papillomavirus Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02236273']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26356Subventions
Organisme : AHRQ HHS
ID : R01 HS022677
Pays : United States
Informations de copyright
©Chelsea S Wynn, Marina Catallozzi, Chelsea A Kolff, Stephen Holleran, Dodi Meyer, Rajasekhar Ramakrishnan, Melissa S Stockwell. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 27.12.2021.
Références
JMIR Pediatr Parent. 2020 Oct 12;3(2):e23057
pubmed: 33001834
Pediatrics. 2015 Nov;136(5):e1220-7
pubmed: 26438703
Prev Med. 2010 May-Jun;50(5-6):306-7
pubmed: 20178813
Front Psychol. 2018 Jun 13;9:735
pubmed: 29951010
J Med Internet Res. 2016 Oct 31;18(11):e287
pubmed: 27806926
Hum Vaccin Immunother. 2019;15(7-8):1549-1561
pubmed: 31158064
JMIR Mhealth Uhealth. 2015 Feb 26;3(1):e20
pubmed: 25803705
Int J Environ Res Public Health. 2019 Mar 04;16(5):
pubmed: 30836685
J Health Commun. 2018;23(1):109-116
pubmed: 29272208
J Adolesc Health. 2015 May;56(5 Suppl):S21-6
pubmed: 25863550
Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941
pubmed: 29342498
BMC Med Inform Decis Mak. 2017 Feb 28;17(1):25
pubmed: 28241759
Pediatrics. 2020 May;145(Suppl 2):S186-S194
pubmed: 32358210
Psychooncology. 2020 Jan;29(1):17-37
pubmed: 31692183
Indian J Cancer. 2018 Oct-Dec;55(4):390-393
pubmed: 30829276
Pediatrics. 2014 Apr;133(4):e835-42
pubmed: 24590751
J Adolesc Health. 2015 May;56(5 Suppl):S17-20
pubmed: 25863549
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1109-1116
pubmed: 32817598
Vaccine. 2011 Mar 21;29(14):2537-41
pubmed: 21300094
Prev Med Rep. 2015 Jun 25;2:554-8
pubmed: 26844117
Pediatr Blood Cancer. 2016 May;63(5):848-52
pubmed: 26844685
Pediatrics. 2011 Jan;127(1):77-84
pubmed: 21149425
Int J Med Inform. 2017 May;101:28-40
pubmed: 28347445
J Korean Acad Nurs. 2013 Aug;43(4):557-67
pubmed: 24071760
Transl Behav Med. 2017 Jun;7(2):254-267
pubmed: 27966189
JMIR Mhealth Uhealth. 2017 Dec 22;5(12):e202
pubmed: 29273573
J Adolesc Health. 2015 May;56(5 Suppl):S27-32
pubmed: 25863551
JMIR Mhealth Uhealth. 2017 Apr 24;5(4):e54
pubmed: 28438728
Pediatrics. 2016 Mar;137(3):e20152857
pubmed: 26921286
J Med Internet Res. 2016 Nov 18;18(11):e307
pubmed: 27864165
JAMA. 2012 Apr 25;307(16):1702-8
pubmed: 22535855
Prev Med. 2013 Aug;57(2):75-80
pubmed: 23624252
J Adolesc Health. 2017 Jan;60(1):113-119
pubmed: 27836533
JMIR Pediatr Parent. 2020 Jun 25;3(1):e20049
pubmed: 32540841
Vaccine. 2019 Feb 8;37(7):984-990
pubmed: 30655175
J Adolesc Health. 2019 Jul;65(1):116-123
pubmed: 30879881
J Med Internet Res. 2018 Jul 19;20(7):e10940
pubmed: 30026178